Asia-Pacific Vaccines Market Size, Share, Competitive Landscape and Trend Analysis Report, by Technology Type, by Indication, by End User : Opportunity Analysis and Industry Forecast, 2024-2033

Key Market Dynamics

The Asia-Pacific vaccines market growth is driven by increase in awareness about immunization, rise in government initiatives for vaccination programs, and ongoing need to prevent and control infectious diseases. In addition, rise in technological advancements in vaccine development, including mRNA technology and innovations in delivery methods, is contributing to Asia-Pacific vaccines market growth. The increasing prevalence of vaccine-preventable diseases, coupled with the need to strengthen healthcare infrastructure, has encouraged greater investment and collaboration in the region which supports the growth during Asia-Pacific vaccines market forecast period. Furthermore, large population and significant proportion of young people, create a robust market for pediatric vaccines and propels the Asia-Pacific vaccines market share.

However, the growth of the market faces certain restraints, such as limited healthcare access in remote and rural areas and high cost of some vaccines. In addition, vaccine hesitancy due to misinformation and cultural barriers poses a challenge to achieving widespread coverage. Despite these challenges, there are significant opportunities for the vaccines market in the Asia-Pacific region. Growing urbanization and rise in middle-class incomes lead to rise in healthcare spending, driving the Asia-Pacific vaccines market share. Partnerships between international health organizations, governments, and pharmaceutical companies provide opportunities to strengthen immunization campaigns, especially in developing countries. The emergence of newer technologies, such as DNA and protein subunit vaccines, leads to development of more effective and accessible immunization options, ensuring broader protection for the population.

Market Segmentation

The Asia-Pacific vaccines market size is segmented on the basis of technology type, indication, end user, and country. On the basis of technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. On the basis of indication, the market is classified into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP) , polio, hepatitis, and other indications. On the basis of end user, the market segmented into pediatric, adults, and travelers. Country-wise the market is classified into Japan, China, India,  Australia,  South Korea, and Rest of Asia-Pacific.

Industry Trends 

• The Sandpiper report from June 2023 emphasizes the importance of vaccine equity in the Asia-Pacific region, projecting significant growth for the vaccine market amid ongoing challenges. Countries such as Australia, China, India, and Japan are taking proactive measures to enhance access for marginalized communities. Australia's use of mobile clinics and community outreach initiatives aims to improve vaccination rates among vulnerable populations. Similarly, China is expanding its National Immunization Program to include a broader range of vaccines. These efforts not only address equity but also stimulate market demand, as increased access leads to higher vaccination rates.

Competitive Landscape

The key players operating in the Asia-Pacific vaccines industry are Chongqing Zhifei Biological Products Co., Ltd, Bharat Biotech, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi, AstraZeneca, Pfizer, CSL, Serum Institute of India Pvt. Ltd., and Vaxine Pty Ltd. These players have adopted various developmental strategies to stay competitive in the market. For instance, in November 2022, CanSino Biologics Inc. announced that it has entered into a strategic collaboration agreement with AstraZeneca. Under the agreement, the two companies will deepen their collaboration to improve Chinese patients’ access to the diagnosis, prevention and treatment of rare diseases. This strategic collaboration agreement primarily covers three areas: clinical research on CanSinoBIO's ACYW135 Meningococcal Conjugate Vaccine for different age groups, development of MCV4 vaccine and complement inhibitors in China for related indications and expansion of accessible patient groups.

Key Benefits for Stakeholders

• The report provides a comprehensive analysis of the current market estimations through 2024-2033, which would enable the stakeholders to capitalize on prevailing market opportunities.
• Major countries are mapped according to their revenue contribution to the Asia-Pacific vaccines market.
• In-depth Asia-Pacific vaccines market analysis and segmentation assists to determine the prevailing market opportunities.
• Identify key players and their strategic moves in Asia-Pacific vaccines market.
• Assess and rank the top factors that are expected to affect the growth of Asia-Pacific vaccines market trends.
• Analyze the market factors in various countries and understand business opportunities.
• Player positioning provides a clear understanding of the present position of key market players.